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Abstract
The prion agent is notoriously resistant to common proteases and conventional sterilisation procedures. The current
methods known to destroy prion infectivity such as incineration, alkaline and thermal hydrolysis are harsh, destructive,
environmentally polluting and potentially hazardous, thus limit their applications for decontamination of delicate medical
and laboratory devices, remediation of prion contaminated environment and for processing animal by-products including
specified risk materials and carcases. Therefore, an environmentally friendly, non-destructive enzymatic degradation
approach is highly desirable. A feather-degrading Bacillus licheniformis N22 keratinase has been isolated which degraded
scrapie prion to undetectable level of PrPSc signals as determined by Western Blot analysis. Prion infectivity was verified by
ex vivo cell-based assay. An enzymatic formulation combining N22 keratinase and biosurfactant derived from Pseudomonas
aeruginosa degraded PrPSc at 65uC in 10 min to undetectable level -. A time-course degradation analysis carried out at 50uC
over 2 h revealed the progressive attenuation of PrPSc intensity. Test of residual infectivity by standard cell culture assay
confirmed that the enzymatic formulation reduced PrPSc infectivity to undetectable levels as compared to cells challenged
with untreated standard scrapie sheep prion (SSBP/1) (p-value = 0.008 at 95% confidence interval). This novel enzymatic
formulation has significant potential application for prion decontamination in various environmentally friendly systems
under mild treatment conditions.
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Introduction
Transmissible Spongiform Encephalopathies (TSEs) or prion
diseases such as Creutzfeldt-Jakob disease (CJD) in humans,
Bovine Spongiform Encephalopathy (BSE) in cattle, Chronic
Wasting Disease (CWD) in mule deer and elk and scrapie in sheep
and goat are a group of closely related, progressive, incurable and
invariably fatal neurodegenerative disorders that affect the central
nervous system (CNS) of mammals [1], [2].
The TSE agent is resistant to common proteases and withstands
conventional physical and chemical sterilisation, inactivation and
decontamination procedures [3-6].
Common prion decontamination methods includes porous load
autoclaving at 134uC for 18 min and immersing contaminated
material in 1 M NaOH and/or 20,000 ppm NaOCl for 1 h at
20uC [1], [7]. However, these methods result in irreversible
damage to medical devices [8], and may be ineffective in
destroying prion infectivity [5], [6], [9].
Incineration [10], [11], thermal hydrolysis [12] and alkaline
hydrolysis [13-15] destroy prions effectively. While incineration is
suitable for destruction of prion in non-recoverable materials, it is
impractical for the decontamination of recoverable and reusable
materials (e.g. animal by-products), delicate medical and labora-
tory instruments, and contaminated environment [16]. Residual
infectivity has also been reported after incineration of scrapie
contaminated tissue [17-19]. In addition, environmental impact
concerns, regulatory requirements and cost of such facility are
limiting factors. Alkaline hydrolysis is unsuitable for application in
the rendering of recoverable Specific Risk Materials (SRM) and
carcases of prion infected tissue as it could result in end products
that are extremely degraded and contain high concentration of salt
residue, therefore diminishing its commercial value [20].
Enzymatic (microbial) degradation of prions has been explored
for the obvious advantages that it is potentially able to destroy
prion infectivity without destroying the decontaminated material.
It is also the most practicable approach for remediation of prion
contaminated environment without adversely affecting the envi-
ronmental biota and/or ecology [21–25].
Since the earliest report of enzymatic degradation of scrapie
prion [26], there have been several studies investigating prion
decontamination [22], [27–33]. In most cases, the prion substrate
was rendered proteolyticly susceptible by either pre-heating at
high temperature, digesting in the presence of chemical surfac-
tants/detergents, denaturants and oxidising agents, incubating
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under high alkaline conditions and digesting for an extended
period of time or a combination of these approaches. The
importance of detergents in the enzymatic degradation mecha-
nism, such as in solubilising the prion substrate, has been
particularly highlighted [22], [29], [30].
In general, the established methods of enzymatic degradation
are harsh, environmentally and economically unsustainable, and
may require a sequential multi-step approach that is complex and
impractical for commercial application. Therefore, a simple,
effective and efficient enzymatic degradation method that
combines moderate pH and temperature conditions, relatively
short digestion time and biological surfactant (biosurfactant) is
highly desirable.
Biosurfactants are extracellular or membrane-associated am-
phiphilic surface-active biomolecules derived from biological
sources [34], [35]. Pseudomonas aeruginosa is one of the prolific
producers of biosurfactants [36], [37]. Biosurfactants are com-
posed of a hydrophilic (head) and hydrophobic (tail) moieties [38],
[39]. The hydrophilic moiety is usually a carbohydrate, amino
acid, phosphate, cyclic peptide, carboxylic acid, or alcohol and the
hydrophobic moiety is mostly a long-chain fatty acid, or fatty acid
derivatives such as hydroxyl fatty acid or a-alkyl-b-hydroxy fatty
acid.
Biosurfactants have various applications in the petroleum
industry [38], [40], environmental bioremediation [41-43],
agricultural biocontrol [44-46] and in cosmetic, pharmaceutical
and therapeutic products industry [35], [39], [47].
This paper reports the degradation of scrapie prion under mild
digestion conditions by a novel enzymatic formulation which
comprises keratinase and biosurfactant isolated from bacterial
sources.
Materials and Methods
Materials
Brain homogenate. Harvested whole brain was homoge-
nized in PBS into 10% (w/v) brain homogenate and stored at
280uC. Subsequently, 1% (w/v) brain homogenate was prepared
in sterile phosphate-buffered saline (PBS) to be used for digestion
experiments. ME7 brain homogenate (kindly provided by Drs
Stephen Whatley and Oduola Abiola of Neuroscience Depart-
ment, KCL Institute of Psychiatry, London), SSBP/1 sheep
scrapie homogenate (kindly provided by the biological archive
Animal Health and Veterinary Laboratories Agency, UK) were
used as scrapie brain homogenate materials, and normal brain
homogenate was derived from C57BL/6 mice.
ME7 brain homogenate was produced under the UK Home
Office Project Licence: ‘Host genetics of prion disease transmis-
sion’ and approved by King’s College London Ethical Review
Process Committee (Denmark Hill Campus). Brain homogenate
from C57BL/6 mice was covered by the licence PPL70/6760:
‘How cells and tissues produce and respond to neurodegenerative
amyloid’ and approved by King’s College London Ethical Review
Process Committee (Guy’s Campus). The SSBP/1 material was
produced under the Home Office Project Licence no. 70/5780
and was approved by the AHVLA Ethical Review Committee. All
work fully met the requirements of the UK Animals (Scientific
Procedures) Act 1986. All infectious scrapie material was handled
according to the World Health Organisations infectious control
guideline for transmissible spongiform encephalopathies [1].
Cell line and culture medium. SSBP/1-susceptible
RK13VRQ.G9 cells were engineered to constitutively express ovine
VRQ PrP allele; RK13 was transfected with a vector containing
the ovine VRQ PrP gene under the control of the CMV promoter.
The vector was described in a paper by Piening et al. [48].
RK13VRQ.G9 cells have similar level of sensitivity as Rov9 cells
[49] to SSBP/1 infection (Neale, unpublished data) and were used
in the standard scrapie cell assay (SSCA). The cells were
maintained in Eagle’s minimal essential medium (EMEM, Gibco)
supplemented with 10% fetal calf serum and 2% HEPES.
RK13VRQ.G9 infection was cultured in OptiMEM medium
(Invitrogen) supplemented with 10% foetal calf serum (Gibco)
and antibiotics/antimyotic (Penicillin, 100 units; Streptomycin,
100 mg and Amphotericin B, 0.25 mg, Invitrogen).
Proteases and biosurfactant. Bacillus licheniformis N22
keratinase (EF) and Pseudomonas aeruginosa NCIMB 8626
biosurfactant (BS) were isolated as previously described [50] and
[51] respectively. An enzymatic formulation (EF+BS) composed of
keratinase and biosurfactant was prepared in the laboratory at
Middlesex University. Proteinase K (PK) was bought from Fisher
scientific, UK.
Assay antibodies. SAF83 (SPI-Bio, France) and Sha31
(Bertin Pharma) were used as primary antibodies to detect PrP
signal in the Western Blot analysis. The secondary antibodies used
were the Amersham ECL sheep anti-mouse IgG Horseradish
peroxidase linked whole antibody (GE Healthcare, UK) and goat
anti-mouse alkaline phosphatase conjugate (Sigma, UK).
Methods
Digestion of brain homogenate substrates. 10 ml of 1%
scrapie-infected brain homogenates (IBH) was digested with PK
(1 ml), EF (1 ml), BS (1 ml) or EF+BS at pH7, digestion times
(ranging from 10 min to 2 h) at 50uC or 65uC as specified for each
experiment. Time-course digestion with EF+BS was carried out
for 30, 45, 60, 90 and 120 min at 50uC, and for 10, 30 and 45 min
at 65uC. EF (0.05, 0.1 and 0.4 mg/ml), BS (75 mg/ml) and PK (10,
50 and 100 mg/ml) final concentrations were investigated to
determine their optimum concentrations. PK-digested and undi-
gested IBH were used as the positive and the negative controls
respectively. Digestion reaction was stopped with 1 ml of 50 mM
Phenyl methyl sulfonyl fluoride (PMSF). All digestions were
carried out in triplicates.
Western Blot Analysis. Digested samples were mixed with
26 sample buffer (11 ml) and heated for 10 min at 100uC on a dry
Figure 1. Western blot profile of ME7 brain homogenate
digested with EF with and without BS. Lanes 2, 3, 4, and 5 are ME7
scrapie brain homogenate digested at 65uC for 1 h with PK (100 mg/ml),
EF+BS, BS and EF respectively. Total removal of PrPSc signal was
achieved with EF+BS only. PrPSc was probed with SAF83 mAb.
doi:10.1371/journal.pone.0068099.g001
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block (Techne, UK). Samples (10 ml) were electrophoresed on
12% gel and the separated proteins were transferred onto
polyvinylidene fluoride (PVDF) membrane by Trans-Blot SD
semi-dry transfer cell (Biorad). The membrane was blocked with
5% skimmed milk for 1 h, and then probed with SAF 83
monoclonal antibody (1:5000) for 1 h while shaking at 30 rpm.
The membrane was washed twice with 0.1% Tween in 16 PBS
(PBST) and a further six washes at 5 min intervals. It was then
probed with sheep anti-mouse IgG Horseradish peroxidase linked
whole antibody (secondary antibody) at 1:5000 dilutions and
incubated at room temperature for 50 min, shaking at 30 rpm and
washed as described above. PrP signal was detected with
AmershamTM ECLTM Plus Western Blot Detection System (GE
Healthcare, UK) as described by the manufacturer. The image
was photographed on Kodak film, and developed with Mediphot
937 X-ray film processor (Colenta Labortechnik, Austria). Each
replicated digested sample was loaded and run on gels for three
separate times.
Standard scrapie cell culture assay (SSCA). The SSCA
was performed at Animal Health and Veterinary Laboratories
Agency, New Haw, Weybridge, UK as previously described [52],
with the only difference being that RK13VRQ.G9 cells was used as
opposed to Rov9 and MovS6 cells, and Sha31 was used instead of
6H4 as the primary antibody. Five different treatments groups
were investigated: IBH (cells inoculated with neat SSBP/1),
Incubated IBH (cells inoculated with SSBP/1 that was incubated
at the digestion temperature), EF (Cells inoculated with N22
keratinase-digested SSBP/1), BS (cells inoculated with biosurfac-
tant-digested SSBP/1) and EF+BS (cells inoculated enzymatic
formulation-digested SSBP/1). All sample digestions were carried
out at 65uC for 1 h. The number of positive cells (spots) were
counted using Zeiss KS-ELISPOT imaging system running
Wellscan software. All experiments were repeated in quadruplet.
Statistical analysis. Test of difference in the number of
infected cells in the treatment groups were compared using Two-
Sample T-Test.
Results
In vitro Degradation of ME7 Scrapie
ME7 scrapie brain homogenate (10 ml) digested with the
enzymatic formulation (EF+BS) at 65uC for 1 h resulted in
undetectable level of PrPSc as determined by Western Blot analysis
(Fig. 1; Lane 3). Under these conditions, keratinase (EF) alone was
unable to completely degrade ME7 scrapie, resulting in the typical
PrPSc glycosylation bands (Fig. 1; Lane 5). Biosurfactant (BS) alone
showed no discernible activity towards PrPSc degradation (Fig. 1;
Lane 4). Digestion with PK resulted in the typical PrPres bands
(Fig. 1; Lane 2).
Time-course degradation carried out at 50uC for 30, 45, 60, 90
and 120 min demonstrated the progressive loss of detectable PrPSc
signal over time (Fig. 2). Further optimisation showed complete
degradation of PrPSc down to undetectable levels in 10 min at
65uC (Fig. 3).
PK at final concentrations of 10, 50 and 100 mg/ml completely
digested normal brain homogenate (NBH) to undetectable levels of
PrP (Fig. 4; lanes: 2–4) but did not digest ME7 infectious brain
homogenate (IBH) beyond the expected reduction in size due to
removal of the N-terminal domain (Fig. 4; lanes: 6–8). Digestion
with the enzymatic formulation (EF+BS) at final concentrations of
EF (0.05, 0.1 and 0.4 mg/ml) and BS (75 mg/ml rhamnose
equivalent) resulted in complete or nearly complete loss of PrPSc
signal in order of increasing dilution (Fig. 4).
Scrapie Cell Assay
To confirm the efficacy of the enzymatic formulation (EF+BS)
to completely eliminate prion infectivity, SSBP/1 susceptible
RK13VRQ.G9 cells were challenged with enzyme-digested SSBP/1
scrapie and analysed for residual infectivity.
Prion infectivity study confirmed that RK13VRQ.G9 cells
propagated SSBP/1 scrapie prion but RK13VRQ.G9 cells inocu-
lated with EF and EF+BS digested SSBP/1 scrapie did not
propagate infectivity as shown by the absence of infected cells
(detectable spots in the ELISPOT assay: Fig. 5). The number of
infected cells per 5000 cells (cell number confirmed by trypan blue
assay) were significantly lower for both the EF and EF+BS
treatment groups compared to the incubated IBH group (both
have p=0.009, Two-Sample T-Test; Fig. 6). Although, a
significantly lower number of cells were infected in the BS
treatment group compared to the incubated IBH group (p=0.033,
Two-Sample T-Test; Fig. 6), the results show that cells inoculated
with BS-treated brain homogenate sample remained infectious
and were able to propagate infection in RK13VRQ.G9 cells. It was
Figure 2. Time-course profile of ME7 brain homogenate
digested with EF+BS at 506C. Lane 1 is neat ME7 brain homogenate
(positive control) and lane 2 is proteinase K treated sample (77 mg/ml
final PK conc.). Lanes 3–7 are digested with EF+BS at 30–120 min
respectively. Samples were digested at 50uC and PrPSc was probed with
SAF83 mAb.
doi:10.1371/journal.pone.0068099.g002
Figure 3. Time-course profile of ME7 brain homogenate
digested with EF+BS at 656C. Lane 1 is neat ME7 brain homogenate
(positive control) and lane 2 is proteinase K digested sample (77 mg/ml
final PK conc.). Lanes 3–6 are digested with EF+BS at 10, 30, 45 and
60 min. Samples were digested at 65uC and PrPSc was probed with
SAF83 mAb.
doi:10.1371/journal.pone.0068099.g003
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also noted that SSBP/1 infectivity was significantly reduced by
incubation at 65uC compared to IBH that was not exposed to
heating (p=0.044, Two-Sample T-Test; Fig. 6).
Discussion
Degradation of ME7 Scrapie Prion
The enzymatic formulation (EF+BS) partially degraded ME7
scrapie prion at 50uC in 1 h but when the temperature was raised
Figure 4. Digestion of normal and ME7 brain homogenates with different concentrations of PK and EF. Normal (NBH) and infected (IBH)
brain homogenates digested at 65uC for 1 h with 10, 50 and 100 mg/ml of proteinase K (lanes 2, 3, 4 and lanes 6, 7, 8 respectively) and EF+BS
formulation [1:50, 1:100 and 1:200 dilutions or 0.4, 0.1 and 0.05 mg/ml of EF and 75 mg/ml rhamnose equivalent (BS)] (lanes 9, 10, 11, 12) probed with
SAF83 monoclonal antibody. Lanes 1 and 5 are undigested NBH and IBH controls, respectively.
doi:10.1371/journal.pone.0068099.g004
Figure 5. Representative photograph of ELISPOT plate. The wells contained infected RK13VRQ.G9 cells inoculated with IBH (SSBP/1), incubated
IBH (heat treated SSBP/1) and BS (Biosurfactant digested SSBP/1). Wells inoculated with SSBP/1 digested with EF and EF+BS were completely devoid
of infected cells. PrPSc was probed with sha31 mAb.
doi:10.1371/journal.pone.0068099.g005
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to 65uC, it was efficiently degraded to levels undetectable by
Western blot analysis in a short digestion time of 10 min (Fig. 3).
This clearly indicates that there was a significant thermal effect on
ME7 prion degradation. Keratinase (EF) alone could not fully
digest ME7 prion at 65uC in 1 h compared to complete digestion
with EF+BS. This suggests a significant role of biosurfactant (BS)
in the degradation mechanism. Therefore, the interplay of
digestion time, temperature and biosurfactant is crucial in
enzymatic prion degradation. In addition, significant level of
PrPSc degradation at low concentration of N22 keratinase (EF)
(0.05 mg/ml) demonstrates the efficacy of this enzyme (Fig. 4).
ME7 scrapie has been reported to be thermally stable up to
84uC [53]. In this study, digestion at 65uC may not have
independently destabilised ME7 scrapie molecular structure but
appears to be a critical factor in the ME7-EF-BS reaction
complex. The catalytic activity of the keratinase and the
solubilising property of biosurfactant were central in the degrada-
tion mechanism, which may also involve PrPSc structure unfold-
ing, weakening of disulphide bonds, proteolytic access and
cleavage of structural bonds as well as substrate solubilisation as
have been previously suggested [22], [54], [55].
BS on its own could not degrade ME7 scrapie suggesting that it
lacked proteolytic activity and prion degrading potential. Some
Pseudomonas strains have been found to produce keratinases [56],
[57] and a Bacillus licheniformis strain have been reported to
concomitantly produce alkaline protease and biosurfactant [58],
but the biosurfactant of Pseudomonas aeruginosa NCIMB 8626
investigated in this study lacked keratinase activity and Bacillus
licheniformis N22 keratinase lacked biosurfactant properties. There-
fore, in this study EF and BS appear to play different but specific
roles, forming a remarkable synergistic effect in the enzymatic
degradation process.
In the time-course experiment, the loss of the PrP band due to
removal of the N-terminal domain suggests the cleavage of PrPSc
by the enzymatic treatment, and further illustrates the interplay of
incubation time and temperature in the prion degradation process.
Therefore, the decision to choose a shorter incubation time over
higher temperature or vice versa will depend on the specific
application need (e.g. decontamination of sensitive surgical device
and remediation of prion contaminated soil) and economic
consideration.
Standard Scrapie Cell Assay (SSCA)
Although Western blot analysis is a commonly used biochemical
method for prion immunodetection, the presence of prion
infectivity in samples with the apparent lack of detectable levels
of PrPSc [59-61] limits its use for evaluating residual prion
infectivity. A more consistent, reliable and sensitive method such
as the SSCA was required to confirm results from Western blot
analysis and to validate the efficacy of the enzymatic formulation
for prion degradation.
SSCA was carried out to establish if the absence of PrPSc
detection in the Western blot profile of the enzyme-digested
SSBP/1 was accompanied by corresponding loss in prion
infectivity. The result of the SSCA confirmed that the enzymatic
formulation efficiently destroyed prion infectivity as shown by the
inability of the enzyme-digested SSBP/1 brain homogenate to
infect susceptible RK13VRQ.G9 cells (Figs 5 and 6). While EF also
destroyed SSBP/1 infectivity, BS resulted in a significant reduction
in the number of infected cells which suggests that SSBP/1
infectivity was significantly attenuated at the digestion temperature
(65uC) but not enough to prevent infection of cells. The number of
spot counts detected in the EF and enzymatic formulation
treatment groups were probably background noise as confirmed
by absence of visually detectable infected cells on the photographic
image of the ELISPOT plate (Fig. 5).
The inability of the enzyme-digested scrapie substrate to
propagate infectivity in the susceptible RK13VRQ.G9 cells suggests
the complete loss of SSBP/1 infectivity. Therefore, the efficacy of
this enzymatic formulation for complete destruction of prion
infectivity has been validated by the SSCA. This result suggests
that the loss of detectable levels of PrPSc signal in the enzyme-
digested scrapie prion as determined by Western blot correlated
with loss of prion infectivity as determined by the SSCA. The
complete destruction of the infectivity of field isolate of sheep
scrapie (SSPB/1) is particularly very important in terms of disposal
of sheep scrapie.
Potential Applications of this Enzymatic Treatment
Method
Hitherto, the inability to achieve efficient prion degradation at
mild digestion conditions (neutral pH, moderate temperature, and
low enzyme concentration) limits the use of enzymatic decontam-
ination in economic and operational terms. Therefore, enzymatic
degradation at mild digestion conditions is of general interest in
the decontamination of sensitive medical devices, animal products
[Meat and Bone Meal (MBM) and SRM] and prion contaminated
environment.
The enzymatic degradation method described in this study
degraded scrapie prion under moderate physical condition (pH 7
and 65uC) and digestion time (10 min). In addition, it did not
require a truncated multi-step approach (e.g. [22], [29], [45]) in
which the infectious material is either pre-treated and/or digested
with multiple enzymes or in the presence of chemical surfactants
or alkali carrier such as NaOH. This enzymatic treatment method
promises to be efficient and practical, and the constituent agents
(N22 keratinase and biosurfactant) are purely biological agents of
potentially low production cost. Thus, this method could provide a
good, environmentally friendly, more economically viable and safe
alternative to existing prion decontamination methods.
Further work will include the decontamination of steel and soil-
bound prion with this enzymatic preparation.
Figure 6. Number of infected cells (spots) for the different
treatment groups. Treatment groups: IBH (inoculated with neat
SSBP/1), Incubated IBH (inoculated with SSBP/1 that was incubated at
the digestion temperature), EF (inoculated with keratinase-digested
SSBP/1), BS (inoculated with biosurfactant-digested SSBP/1) and EF+BS
(inoculated with enzymatic formulation-digested SSBP/1). The number
of infected cells were significantly reduced for EF (p= 0.009), BS
(p= 0.033) and EF+BS (p= 0.009) treatment groups compared to
Incubated IBH. Test of significance was calculated using Two-Sample
T-Test. Each bar represents mean 6 SD (n = 4, each data point).
doi:10.1371/journal.pone.0068099.g006
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Use of Biosurfactant in Prion Degradation
Chemical surfactants/detergents enhance enzymatic prion
degradation [22], [26], [29], [31], [62], [63]. However, biosurfac-
tants are particularly useful and advantageous because of their
environmentally friendly properties (e.g. low toxicity, high
biodegradability) and their biochemical properties enabling
lowering of surface tension, increasing substrate surface area,
substrate solubilisation and protein unfolding [32], [64]. In
addition, biosurfactants inhibit pathogen adhesion and formation
of biofilms on steel surfaces [35], [46], presenting a two fold
advantage for decontamination of steel surfaces such as medical
devices. Using biosurfactant would also prevent undesirable
chemical load in the enzymatic degradation processes, and the
need for additional facilities for effluent treatment.
This is the first report on the use of biosurfactant in the
degradation of prion. In this study, crude biosurfactant was used
resulting in substantial saving in cost and labour associated with
biosurfactant purification.
Conclusion
A novel enzymatic formulation combining keratinase and
biosurfactant in a remarkable synergy which efficiently degraded
scrapie prion and destroyed its infectivity has been reported. This
system has great potential for use in the environmentally friendly
prion decontamination processes of surgical instruments and
recoverable materials in general.
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